Duisburg

• A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges … Not authorised
  2025-521764-35-00 5 acute pharyngitis
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending
  2023-507427-28-00 5 seasonal allergic rhinitis and/or rhinoconjunctivitis
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 D … Pending
  2024-520068-32-00 6 Type 2 diabetes
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 Immune system diseases
• A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending
  2025-522855-25-00 5 Carcinoma, Transitional Cell
• Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH). Pending
  2025-523672-23-00 4 Metastatic Castrate Sensitive Prostate Cancer - mCSPC
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting
  2024-515622-80-00 5 2025-06-04 Type 3 Von Willebrand Disease
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS … Recruiting
  2022-500479-29-00 10 2023-03-28 International Prognostic Scoring System-Revised (IPSS-R) Low - or Inte
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting
  2024-515830-34-00 5 2023-02-14 Congenital antithrombin deficiency
• A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t … Recruiting
  2022-500461-28-06 5 2022-09-15 High-Risk Metastatic Hormone-Sensitive Prostate Cancer
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all … Recruiting
  2025-524580-21-00 10 2026-06-01 Grass pollen induced allergic rhinitis or rhinoconjunctivitis
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1). Recruiting
  2025-523657-34-00 5 2026-04-13 Obesity
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-522713-29-00 5 2026-03-12 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases

Showing 1–24 of 70 trials